Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
Ipilimumab (Yervoy; Medarex and Bristol-Myers Squibb) is a human MAB against cytotoxic T-lymphocyte antigen 4, which enhances co-stimulation of cytotoxic T-lymphocytes, resulting in their proliferation and an anti-tumour response. It is licensed for the treatment of unresectable or metastatic malignant melanoma, while multiple clinical trials using this medication in the treatment of other malignancies are ongoing. As a clinical response to ipilimumab results from immunostimulation, predictab...Expand abstract
- Publication status:
- Publisher copy:
- European journal of endocrinology / European Federation of Endocrine Societies
- Publication date:
- Source identifiers:
- Copyright date: